Skip to main content

Drug Updates

Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma

By Lisa A. Raedler, PhD, RPh

May 2016, Vol 6, No 5

Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma

By Lisa A. Raedler, PhD, RPh

Drug Updates, Hematologic Malignancies, Multiple Myeloma

April 2016, Vol 6, No 4

Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

By Lisa A. Raedler, PhD, RPh

March 2016, Vol 6, No 3

Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer

By Lisa A. Raedler, PhD, RPh

February 2016, Vol 6, No 2

Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1

By Lisa A. Raedler, PhD, RPh

January 2016, Vol 6, No 1

Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer

By Lisa A. Raedler, PhD, RPh

Breast Cancer, Drug Updates

October 2015, Vol 5, No 7

Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma

Drug Updates, Multiple Myeloma, Hematologic Malignancies

September 2015, Vol 5, No 6

Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera

By Lisa A. Raedler, PhD, RPh

June 2015, Vol 5, No 5

Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting

By Lisa A. Raedler, PhD, RPh

May 2015, Vol 5, No 4

Sunitinib Associated with Higher Costs Compared with Pazopanib in Patients with RCC

May 2015, Vol 5, No 4

Page 3 of 4

1
2
3
4